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Calcification of bioprosthetic heart valves and its
assessment
Jeffrey M. Gross, PhD
Be not the first by whom the new are tried, Nor yet the last to lay the old aside.
—Alexander Pope, An Essay on Criticism
This quotation befits the surgical community as it collectively pondershow much technology to embrace with respect to current and futurebioprosthetic heart valve designs. It can be argued that currentregulatory guidance document governing development of these pros-theses adequately safeguards against the potential for catastrophicstructural failures decoupled from biologic influence, for example,
stent fracture and tissue dehiscence. The current state of preclinical assessment for
the “biologic degradation” of the valvular components is not as predictive given the
inherent variability and complexity of the human biologic system into which these
devices are implanted. Granted, preclinical evaluation in a variety of animal models
is used to access a valve design’s functionality and resistance to calcification;
however, it is often difficult to extrapolate such data to the long-term human
experience.
The intent of this editorial is to provide a broad overview of what is thought to
be the mechanisms of calcification in bioprosthetic heart valves, list the current
fixation processes in the literature, and examine how prostheses are evaluated for
their antimineralization efficacy. Above all, it is my hope that this editorial will spur
thought and challenge industrial, clinical, and academic scientists to seek better
techniques for the evaluation of new tissue fixation processes.
Glutaraldehyde-fixed heart valves were first implanted in 1967 after it was
determined that glutaraldehyde stabilized collagenous biomaterials.1,2 Although
valves thus treated were nonthrombogenic, they failed because of calcific degener-
ation.3,4 Much has been written yet little has been proven as to the mechanisms for
this calcification. It has been postulated that calcium phosphate crystals containing
sodium, magnesium, and carbonate nucleate due to devitalization of the cells and
thus inactivation of the calcium pump.5 It has been demonstrated that calcification
does initiate in the cells6; however, this would appear to be at odds with the fact that
cusps stored in glutaraldehyde for more than 1 year no longer calcify,7 and valves
treated with high concentrations of glutaraldehyde have diminished calcification.8 In
both cases, cells and their remnants are present in the collagen/elastin matrix. For
this reason, work has also focused on decellularization of the porcine collagen/
elastin matrix.9 Membrane-bound phospholipids have also been associated with
calcification nucleation due to alkaline phosphatase hydrolysis.10 Ethanol has been
used to remove phospholipids and mitigate calcification, yet phospholipids have
also been removed with chloroform-methanol yielding less than optimum antimin-
eralization efficacy on the basis of rat subcutaneous experiments.11 This would
indicate that phospholipid removal alone is not sufficient to mitigate calcification.
Lipid extraction can also be performed through tissue processing with detergent
compounds such as sodium dodecyl sulfate. Subcutaneous rat studies indicate this
approach to be efficacious, although circulatory models have demonstrated mixed
results.12 The primary concern with lipid extraction methods is the potential for
collagen matrix degradation if the processes are too aggressive.10 Free aldehyde
within the tissue matrix has been thought to be an initiator for calcification as well.
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This is supported by studies that demonstrate that aldehyde-
binding agents such as alpha-amino oleic acid (AOA; Bio-
medical Design, Marietta, Ga), L-glutamic acid, and amino-
diphosphonate prevent cusp calcification.13-16 Yet, post
treatment with the amino acid lysine does not prevent cuspal
calcification.17 The foregoing often conflicting information
serves to underscore the complexity of the bioprosthetic
valve calcification process and emphasizes the multiplicity
of pathways by which calcification can initiate.
Because theories for bioprosthetic valve calcification ex-
ist without definitive proof, the approaches used by industry
and researchers to seek solutions to this clinical failure
modality have been based on observed phenomena. Pro-
cesses have been developed and then assessed to ensure
reproducibility, desired tissue biomechanics, desired surface
chemistry, matrix stability, and resistance to calcification
through a battery of in vitro and in vivo tests. A variety of
treatments have been used clinically as well as experimen-
tally. They may be broken down into two broad categories:
modifications to glutaraldehyde processed tissue and non-
glutaraldehyde processes. The modifications to glutaralde-
hyde processed tissue include but are not limited to treat-
ments with detergents such as sodium dodecyl sulfate and
Tween-80 to remove phospholipids,12 ethanol preincubation
to remove phospholipids,11 covalently bound AOA, L-glu-
tamic acid and aminodiphosphonate to bind free alde-
hydes,13-17 and detoxification processes using urazole18 and
homocysteic acid.19 Nonglutaraldehyde processes include
but are not limited to epoxy compounds,20 dye-mediated
photo-oxidative reactions including PhotoFix21 (Sulzer Car-
bomedics, Austin, Tex) and carbodiimide compounds in-
cluding Ultifix (Biomedical Design).22
Some of these processes have clinical experience and
some do not. Clinical data are difficult to access relative to
bioprosthetic valvular calcification, because valves are not
usually explanted unless demonstrable valvular perform-
ance issues are present that cause stenosis and/or incompe-
tence. This is further confounded by the fact that one must
also layer into the analysis the host of patient factors that
can bias interpretations. The resulting analysis in general
yields a statement as to whether a valve was calcified or not.
Although this is valuable, it does not provide insight as to
the mechanism for the presence of or lack of calcification.
This may change, however. A recent publication by Melina
and associates23 demonstrated a real time in vivo technique
using electron beam computed tomography to assess calci-
fication in both aortic leaflets and aortic wall with stentless
xenografts and homografts. This represents a first hope at
getting the mechanistic question answered noninvasively in
human beings.
The root cause for our inability to determine the mech-
anisms for bioprosthetic heart valve calcification lies in the
limitations of the models we use in the pursuit of this
knowledge. Current preclinical in vivo techniques for the
assessment of bioprosthetic heart valve calcification revolve
around analysis of explants from two animal models—the
rat subcutaneous model and the juvenile sheep. Values for
calcification from the rat subcutaneous model favorably
trend with those from the juvenile sheep.10,11 Thus, despite
being static and lacking blood contact, the rat subcutaneous
model can be used to screen processes before committing to
the expense of large animal studies. In addition to the
standard 8-week implant duration reported by most inves-
tigators using the subcutaneous rat model, spatial studies
should be undertaken with freshly processed and aged shelf
life valves to ensure any effect noted is in fact present as
opposed to simply offset in time.24 The sheep model uses an
orthotopic implant. As such, it is blood contacting and
integrates the unknown role of cyclic mechanical stress into
the determination of calcification resistance. The downfall
is that, because of the time and expense associated with
conducting such studies, the use of statistically valid sample
sizes is prohibitive, rendering results difficult to interpret
should biologic variation occur. In general, the predictive
capacity of both models suffers from differences between
their lipoprotein profile and accelerated calcium metabolism
as compared with human beings. Neither incorporates the
cardiovascular disease effects and neither accurately reflects
the coagulation pathways of human beings. The latter is
important, as at present there is no validated thromboem-
bolism model for the assessment of modified and/or new
tissue fixation/stabilization technology incorporated into
heart valve designs.
Given the limitations of preclinical in vivo bioprosthetic
valvular calcification assessment techniques, researchers
have long sought to develop in vitro methods. Calcium-rich
solutions have been applied to bioprosthetic valves placed
into dynamic operation in vitro at a variety of frequen-
cies.25-27 The limitation of this technique revolves not
around the ability to produce calcification but to correlate
the histologic and ultrastructural manifestation of this cal-
cification to that seen in the animal models and in human
beings. In this issue of the Journal [J Thorac Cardiovasc
Surg 2001;121:500-9], Pettenazzo and associates describe
their in vitro test system and results. They were able to
produce extrinsic nodular and laminar calcific deposits. The
intrinsic calcification noted on the basis of transmission
electron microscopic analysis was associated at the micro-
structural level with collagen and elastin fibrils. Most nota-
bly, however, they saw minimal calcification associated
with xenograft cells and cellular debris. This is at odds with
evidence reported from biologic models and human ex-
plants.5,6 This is not to say that such modeling is not
valuable. Rather, it underscores the need for additional
validations with this technology. Greater sample size is
necessary to ensure the model’s sensitivity. Spatial studies
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must be completed to determine apatite initiation sites and
their growth characteristics, and processes with data from
animal models should be assessed in the present in vitro
model to determine whether a correlation exists.
The ultimate answer is that no single model or analysis
will contain the necessary predictive power to determine a
bioprosthetic heart valve’s potential to calcify. The key to
the assessment of bioprosthetic valvular calcification lies in
the usage of multiple models and the understanding of their
limitations. As we collectively move the state of the art
forward for the assessment of calcification efficacy with
bioprostheses, the patients receiving these devices will ul-
timately benefit because new technology will have lower
risk with greater hope of demonstrating clinical efficacy.
Once achieved and borne out by the scrutiny of science, we
can then say, on this one issue, that Alexander Pope’s first
comment should not apply.
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